These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36053771)

  • 41. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
    Modi S
    Future Oncol; 2021 Sep; 17(26):3415-3423. PubMed ID: 34263665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
    Siena S; Di Bartolomeo M; Raghav K; Masuishi T; Loupakis F; Kawakami H; Yamaguchi K; Nishina T; Fakih M; Elez E; Rodriguez J; Ciardiello F; Komatsu Y; Esaki T; Chung K; Wainberg Z; Sartore-Bianchi A; Saxena K; Yamamoto E; Bako E; Okuda Y; Shahidi J; Grothey A; Yoshino T;
    Lancet Oncol; 2021 Jun; 22(6):779-789. PubMed ID: 33961795
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
    Tsurutani J; Iwata H; Krop I; Jänne PA; Doi T; Takahashi S; Park H; Redfern C; Tamura K; Wise-Draper TM; Saito K; Sugihara M; Singh J; Jikoh T; Gallant G; Li BT
    Cancer Discov; 2020 May; 10(5):688-701. PubMed ID: 32213540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.
    Perez J; Garrigós L; Gion M; Jänne PA; Shitara K; Siena S; Cortés J
    Expert Opin Biol Ther; 2021 Jul; 21(7):811-824. PubMed ID: 33759669
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells.
    Nakajima S; Mimura K; Matsumoto T; Thar Min AK; Ito M; Nakano H; Neupane P; Kanke Y; Okayama H; Saito M; Momma T; Watanabe Y; Hanayama H; Hayase S; Saze Z; Kono K
    Sci Rep; 2021 Aug; 11(1):16891. PubMed ID: 34413454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. T-DXd: New Standard for HER2-Low Breast Cancer.
    Cancer Discov; 2022 Aug; 12(8):1828. PubMed ID: 35666611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors.
    Yonesaka K
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801379
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for
    Azar I; Alkassis S; Fukui J; Alsawah F; Fedak K; Al Hallak MN; Sukari A; Nagasaka M
    Lung Cancer (Auckl); 2021; 12():103-114. PubMed ID: 34675733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
    Lu D; Girish S; Gao Y; Wang B; Yi JH; Guardino E; Samant M; Cobleigh M; Rimawi M; Conte P; Jin JY
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):399-410. PubMed ID: 24939213
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
    Mukai H; Saeki T; Aogi K; Naito Y; Matsubara N; Shigekawa T; Ueda S; Takashima S; Hara F; Yamashita T; Ohwada S; Sasaki Y
    Cancer Sci; 2016 Oct; 107(10):1465-1470. PubMed ID: 27452985
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
    Ohba A; Morizane C; Ueno M; Kobayashi S; Kawamoto Y; Komatsu Y; Ikeda M; Sasaki M; Okano N; Furuse J; Hiraoka N; Yoshida H; Kuchiba A; Sadachi R; Nakamura K; Matsui N; Nakamura Y; Okamoto W; Yoshino T; Okusaka T
    Future Oncol; 2022 Jun; 18(19):2351-2360. PubMed ID: 35510484
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.
    Kabraji S; Ni J; Sammons S; Li T; Van Swearingen AED; Wang Y; Pereslete A; Hsu L; DiPiro PJ; Lascola C; Moore H; Hughes M; Raghavendra AS; Gule-Monroe M; Murthy RK; Winer EP; Anders CK; Zhao JJ; Lin NU
    Clin Cancer Res; 2023 Jan; 29(1):174-182. PubMed ID: 36074155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
    Chen SC; Kagedal M; Gao Y; Wang B; Harle-Yge ML; Girish S; Jin J; Li C
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1147-1159. PubMed ID: 29043411
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.
    Nakajima H; Harano K; Nakai T; Kusuhara S; Nakao T; Funasaka C; Kondoh C; Matsubara N; Naito Y; Hosono A; Mitsunaga S; Ishii G; Mukohara T
    Breast; 2022 Feb; 61():136-144. PubMed ID: 34999427
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
    Takegawa N; Tsurutani J; Kawakami H; Yonesaka K; Kato R; Haratani K; Hayashi H; Takeda M; Nonagase Y; Maenishi O; Nakagawa K
    Int J Cancer; 2019 Dec; 145(12):3414-3424. PubMed ID: 31087550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
    Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
    Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review.
    Abuhelwa Z; Alloghbi A; Alqahtani A; Nagasaka M
    Drugs; 2022 Jun; 82(9):979-987. PubMed ID: 35759121
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model.
    Iwata TN; Sugihara K; Wada T; Agatsuma T
    PLoS One; 2019; 14(10):e0222280. PubMed ID: 31574081
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer.
    Kotani D; Shitara K
    Ther Adv Med Oncol; 2021; 13():1758835920986518. PubMed ID: 33473250
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
    Chen X; Li C; Ewesuedo R; Yin D
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.